None listed
Conditions
Brief summary
Pulmonary embolism (blood clots in the lungs) is a common, potentially life-threatening condition affecting 50 to 75 per 100,000 people each year in Australia. The current long-term treatment of blood clots is limited to blood thinners alone, and there are no other studies investigating different treatment approaches. Mechanisms that determine persistence of blood clots in the lung blood vessels despite adequate blood thinning treatment remain unknown. Inflammation within the blood vessel walls following a blood clot seems to be an important driver of impaired clot resolution, but treatments targeting inflammation within the blood vessels are limited. Glucagon-like peptide-1 (GLP-1) agonists, which are commonly used in diabetes treatment, have prominent anti-inflammatory and blood vessel relaxation properties supporting their use in patients with lung blood clots at higher risk of worse outcomes. The purpose of this study is to test a novel treatment approach with a once-a-day medication (Liraglutide), in hospitalised patients with acute lung blood clots.
Interventions
Liraglutide 0.6mg once daily subcutaneously for 5 days with standard of care anticoagulation for hospitalised patients with acute pulmonary embolism. The intervention medication will be administered by the study investigators to ensure compliance. The standard of care anticoagulation treatment will be determined by the treating clinical team and the adherence will be monitored using medication charts.
Sponsors
Western Sydney Local Health District
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients aged greater than or equal to 18 years and able to consent. Acute intermediate or high-risk pulmonary embolism. Initiated on anticoagulation on hospital admission. Evidence of right ventricular dysfunction on admission.
Exclusion criteria
Significant co-existent pulmonary and/or cardiac disease Contraindications to use of GLP-1 agonists. Currently taking GLP-1 agonist for diabetes mellitus. Currently taking insulin or a sulfonylurea for diabetes mellitus.
Outcome results
None listed